Q-omics provides the consensus-scored PTP4A1 profile across patient tissues and cancer cell-line models. PTP4A1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTP4A1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PTP4A1 protein abundance shows 22,445 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KICH, and GBM as cancer lineages where PTP4A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTP4A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTP4A1 survival associations across molecular data types. PTP4A1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTP4A1 RNA expression–survival associations across cancer types. High PTP4A1 expression shows unfavorable associations in HNSC, CESC, KIRP and MESO, but favorable associations in KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTP4A1 RNA expression.
This table summarizes PTP4A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PTP4A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTP4A1 shows lower tumor expression in KICH, COAD, BLCA, READ and KIRC and higher tumor expression in HNSC. The KICH box plot shows higher PTP4A1 RNA expression in normal versus tumor tissue (log2 FC = −2.947, t-test p < 0.001).
This table shows molecular features associated with PTP4A1 in patient tissues and cancer cell lines. In patient samples, PTP4A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTP4A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
